Lifecome Biochemistry Co Ltd (002868) — Working Capital to Net Assets Ratio
Lifecome Biochemistry Co Ltd (002868) has a Working Capital to Net Assets ratio of -479.5% as of June 2026. Working capital of CN¥-346.90 Million (current assets of CN¥199.48 Million minus current liabilities of CN¥546.39 Million) is measured against net assets of CN¥72.35 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See 002868 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Lifecome Biochemistry Co Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Lifecome Biochemistry Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at -479.5%, reflecting working capital of CN¥-346.90 Million against net assets of CN¥72.35 Million CNY. For the complete balance sheet picture, see balance sheet size of Lifecome Biochemistry Co Ltd.
Annual Working Capital to Net Assets for Lifecome Biochemistry Co Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Lifecome Biochemistry Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 002868 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -599.9% | CN¥-389.55 Million | CN¥64.93 Million | CN¥207.68 Million | CN¥597.24 Million | ▼ -4783.5 pp |
| 2024 | 4183.6% | CN¥-1.03 Billion | CN¥-24.54 Million | CN¥216.22 Million | CN¥1.24 Billion | ▲ +4292.7 pp |
| 2023 | -109.1% | CN¥-451.92 Million | CN¥414.11 Million | CN¥478.39 Million | CN¥930.31 Million | ▼ -112.6 pp |
| 2022 | 3.4% | CN¥20.66 Million | CN¥599.30 Million | CN¥505.80 Million | CN¥485.14 Million | ▲ +25.9 pp |
| 2021 | -22.5% | CN¥-162.36 Million | CN¥722.02 Million | CN¥227.97 Million | CN¥390.34 Million | ▼ -45.6 pp |
| 2020 | 23.1% | CN¥177.76 Million | CN¥769.94 Million | CN¥304.58 Million | CN¥126.82 Million | ▼ -34.5 pp |
| 2019 | 57.6% | CN¥448.63 Million | CN¥778.50 Million | CN¥586.27 Million | CN¥137.64 Million | ▼ -1.3 pp |
| 2018 | 59.0% | CN¥436.47 Million | CN¥740.37 Million | CN¥488.22 Million | CN¥51.75 Million | ▼ -5.0 pp |
| 2017 | 64.0% | CN¥445.04 Million | CN¥695.68 Million | CN¥495.92 Million | CN¥50.89 Million | ▲ +59.8 pp |
| 2016 | 4.2% | CN¥11.36 Million | CN¥271.34 Million | CN¥96.81 Million | CN¥85.44 Million | ▲ +18.3 pp |
| 2015 | -14.1% | CN¥-33.67 Million | CN¥238.98 Million | CN¥93.00 Million | CN¥126.67 Million | ▲ +20.7 pp |
| 2014 | -34.8% | CN¥-66.34 Million | CN¥190.87 Million | CN¥97.19 Million | CN¥163.53 Million | ▲ +9.6 pp |
| 2013 | -44.3% | CN¥-75.12 Million | CN¥169.42 Million | CN¥100.22 Million | CN¥175.34 Million | ▼ -16.0 pp |
| 2012 | -28.3% | CN¥-44.26 Million | CN¥156.45 Million | CN¥105.48 Million | CN¥149.74 Million | — |